Neumonitis por docetaxel, discusión de un caso
DOI:
https://doi.org/10.35509/01239015.67Keywords:
Consolidation Chemotherapy, Interstitial Lung Diseases, Prostate NeoplasmsAbstract
Interstitial pneumonitis due to docetaxel is an infrequent event but with a high mortality potential; it can be potentially reversible with the use of systemic steroids and is considered important in the differential diagnosis of the patient undergoing chemotherapy with respiratory symptoms. We present a case of fatal pneumonitis due to docetaxel in a patient with advanced prostate carcinoma. An 80-year-old patient with a history of prostate cancer of 15 years of evolution, with disease progression in bones and lymph nodes, in whom treatment with Docetaxel was started, after the application of the third cycle, he presented with dyspnea on exertion, fever, dry cough and general deterioration. A diagnosis of pneumonitis due to docetaxel was made, discarding other entities. Interstitial pneumonitis due to docetaxel is a rare entity. The pillars of the treatment are the suspension of the medication, the ventilatory support and the use of systemic glucocorticoids.
Author Biographies
Juan Ramírez, Hospital Pablo Tobón Uribe
Grupo de Medicina Interna, Hospital Pablo Tobón Uribe, Medellín, Colombia
Sergio Mejía, Universidad Pontificia Bolivariana
Medicina Interna, Universidad Pontificia Bolivariana, Medellín, Colombia
Alicia Quiroga, Hospital Pablo Tobón Uribe
Grupo de Oncología Clínica, Hospital Pablo Tobón Uribe, Medellín, Colombia
References
https://doi.org/10.4111/kju.2012.53.5.371
2. Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res. 2014;6:253-9.
https://doi.org/10.2147/CMAR.S40601
3. Ochoa R, Bejarano P, Gluck S, Montero AJ. Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophospamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep. 2012;6:413.
https://doi.org/10.1186/1752-1947-6-413
4. Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, et al. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Antican Res. 2012;32(3):1103-6.
5. Storass E, Holmaas G, Gravdal K, Borretzen A, Eikesdal HP. Lethal pneumonitis after docetaxel chemotherapy: case report and review of the literature. Acta Oncologica, 2013;52:1034-54.
https://doi.org/10.3109/0284186X.2012.750734
6. Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer. 2002;94:847-53.
https://doi.org/10.1002/cncr.10263
7. Wang GS, Yan KY, Perng RP. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer. 2001;85(9):1247-50.
https://doi.org/10.1054/bjoc.2001.2071
8. Kuip E, Muller E. Fatal pneumonitis after treatment with docetaxel and trastuzumab. Neth J Med. 2009;67(6):237-9.
9. Alsamarai S, Charpidou AG, Matthay RA, Confeld D, Syrigos KN, Saif MW, et al. Pneumonitis related to docetaxel: case report and review of the literature. In vivo. 2009;23(4):635- 8.
10. Taj A. Docetaxel-induced hypersensitivity pneumonitis mimicking lymphangitic carcinomatosis in a patient with metastastic adenocarcinoma of the lung. Hematol Oncol Stem Cell Ther. 2013;6(3-4):117-9.
https://doi.org/10.1016/j.hemonc.2013.08.005
11. Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol. 2006;24(31):4963-70.
https://doi.org/10.1200/JCO.2005.05.0294
12. Binder D, Hübner RH, Temmesfeld-Wollbrück B, Schlattmann P. Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a metaanalysis of clinical trials. Cancer Chemother Pharmacol.2011;68(6):1575-83.
https://doi.org/10.1007/s00280-011-1648-2
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
